Celldex reports Phase 2 data on glembatumumab vedotin in melanoma
Celldex Therapeutics presented results from the company's Phase 2 study of glembatumumab vedotin in patients with stage III/IV checkpoint inhibitor-refractory, and, if applicable, BRAF/MEK inhibitor-refractory metastatic melanoma. The primary endpoint of the study -- 6 or more objective responses in the first 52 patients enrolled -- was exceeded. Seven of 62 patients experienced a confirmed response, and an additional 3 patients also experienced single timepoint responses. Median duration of response in this heavily pre-treated patient population was 6.0 months. 53% of patients experienced stable disease, with a minimum duration of six weeks. A 52% disease control rate was demonstrated. 52% of patients experienced tumor shrinkage. Median progression-free survival for all patients was 4.4 months. Patients who experienced rash in Cycle 1 experienced a 20% confirmed response rate and a more prolonged PFS of 5.5 months.